TY - JOUR
T1 - Adult acute myeloid leukaemia
AU - Smith, Matthew
AU - Barnett, Michael
AU - Bassan, Renato
AU - Gatta, Gemma
AU - Tondini, Carlo
AU - Kern, Wolfgang
PY - 2004/6
Y1 - 2004/6
N2 - The curability of acute myeloid leukaemia (AML) in a fraction of adult patients was demonstrated a long time ago. Currently, the probability of cure is consistently above fifty per cent in patients with de novo disease expressing favourable-risk associated cytogenetic features. Even better, the cure rate exceeds 75% in the acute promyelocytic subtype since the introduction of retinoic acid-containing regimens. In the meantime, continuing progress in supportive care systems and stem cell transplant procedures is making myeloablative therapies, when needed, somewhat less toxic - and thereby more effective - than in the recent past. Therefore, evidence is accumulating to indicate an improved therapeutic trend over the years, with the notable exception of older (>55 years) patients with adverse-risk chromosomal aberrations and/or leukemia secondary to myelodysplasia or prior cancer-related chemotherapy and/or radiotherapy. This review conveys the many facets of this progress, focusing on diagnostic subsets, risk classes, newer biological issues and conventional as well as innovative therapeutic interventions with or without autologous/allogeneic stem cell transplantation.
AB - The curability of acute myeloid leukaemia (AML) in a fraction of adult patients was demonstrated a long time ago. Currently, the probability of cure is consistently above fifty per cent in patients with de novo disease expressing favourable-risk associated cytogenetic features. Even better, the cure rate exceeds 75% in the acute promyelocytic subtype since the introduction of retinoic acid-containing regimens. In the meantime, continuing progress in supportive care systems and stem cell transplant procedures is making myeloablative therapies, when needed, somewhat less toxic - and thereby more effective - than in the recent past. Therefore, evidence is accumulating to indicate an improved therapeutic trend over the years, with the notable exception of older (>55 years) patients with adverse-risk chromosomal aberrations and/or leukemia secondary to myelodysplasia or prior cancer-related chemotherapy and/or radiotherapy. This review conveys the many facets of this progress, focusing on diagnostic subsets, risk classes, newer biological issues and conventional as well as innovative therapeutic interventions with or without autologous/allogeneic stem cell transplantation.
KW - Acute myeloid leukaemia (AML)
KW - Diagnosis
KW - Prognosis
KW - Recommendations
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=2942558845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942558845&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2003.11.002
DO - 10.1016/j.critrevonc.2003.11.002
M3 - Article
C2 - 15182826
AN - SCOPUS:2942558845
VL - 50
SP - 197
EP - 222
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 3
ER -